EQL Pharma
79.8
SEK
+1.01 %
EQL
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+1.01%
+26.67%
+45.62%
+58.96%
+138.92%
+136.09%
+126.06%
+523.44%
+1,384.72%
EQL Pharma is a pharmaceutical company. Currently, the focus is on development of niche and specialised pharmaceuticals, including everything from pharma for the treatment of diabetes, enlargement of blood vessels, as well as various infections and allergies. Primarily business is found in the Nordic market. EQL Pharma was founded in 2006 and is based in Lund.
Read moreMarket cap
2.32B SEK
Turnover
837.19K SEK
Revenue
264.17M
EBIT %
12.35 %
P/E
102.31
Dividend yield-%
-
Financial calendar
5/2
2025
Interim report Q3'25
8/5
2025
Annual report '25
21/8
2025
General meeting '25
ShowingAll content types
Carnegie Commissioned Research: EQL Pharma: Expands portfolio with strategic asset acquisition
Rättelse: EQL Pharma AB (publ) ingår ett inkråmsöverlåtelseavtal avseende förvärv av en portfölj med originalläkemedel
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools